5-Aminolevulinic acid hydrochloride 5-氨基乙酰丙酸盐酸盐; 5-ALA hydrochloride; δ-Aminolevulinic acid hydrochloride; 5-Amino-4-oxopentanoic acid hydrochloride,98.0%
产品编号:Bellancom-N0305| CAS NO:5451-09-2| 分子式:C5H10ClNO3| 分子量:167.59
5-Aminolevulinic acid盐酸盐是体内血红素生物合成的中间体,为四吡咯的前体。
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
5-Aminolevulinic acid hydrochloride 5-氨基乙酰丙酸盐酸盐; 5-ALA hydrochloride; δ-Aminolevulinic acid hydrochloride; 5-Amino-4-oxopentanoic acid hydrochloride
产品介绍 | 5-Aminolevulinic acid hydrochloride (5-ALA hydrochloride) 是体内血红素生物合成的中间体,为四吡咯的前体。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | 5-Aminolevulinic acid hydrochloride (5-ALA hydrochloride) is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles. | ||||||||||||||||
体外研究 |
5-Aminolevulinic acid hydrochloride (ALA) is a non-fluorescent prodrug that leads to intracellular accumulation of fluorescent porphyrins in malignant gliomas-a finding that is under investigation for intraoperative identification and resection of these tumours. Median follow-up was 35.4 months (95% CI 1.0-56.7). Contrast-enhancing tumour was resected completely in 90 (65%) of 139 patients assigned 5-aminolevulinic acid compared with 47 (36%) of 131 assigned white light (difference between groups 29% [95% CI 17-40], p<0.0001). Patients allocated 5-aminolevulinic acid had higher 6-month progression free survival than did those allocated white light (41.0% [32.8-49.2] vs 21.1% [14.0-28.2]; difference between groups 19.9% [9.1-30.7], p=0.0003, Z test) . 5-ALA alone proved to be insufficient in attaining gross total resection without the danger of incurring postoperative neurological deterioration. Furthermore, in the case of functional grade III gliomas, iMRI in combination with functional neuronavigation was significantly superior to the 5-ALA resection technique . 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 | |||||||||||||||||
体内研究 | |||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (596.69 mM; Need ultrasonic) H2O : 16.67 mg/mL (99.47 mM; ultrasonic and warming and heat to 60°C) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
参考文献 |
|
符号 |
![]() GHS07 |
---|---|
信号词 | Warning |
危害声明 | H315-H319 |
警示性声明 | P305 + P351 + P338 |
个人防护装备 | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
危害码 (欧洲) | Xi,Xn |
风险声明 (欧洲) | R36/37/38:Irritating to eyes, respiratory system and skin . R66:Repeated exposure may cause skin dryness or cracking. R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . |
安全声明 (欧洲) | S26-S36/37-S37/39 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
RTECS号 | OI1640000 |
海关编码 | 2922509090 |
上游产品 7 | |
---|---|
下游产品 6 | |

匹配竞争对手的价格

效率为先

专业经验 贴心服务

50000+库存